The Neuromuscular Junction: A Shared Vulnerability in Aging and Disease.
Kathryn R Moss, Fereshteh B Darvishi, Yomna Badawi...
https://pubmed.ncbi.nlm.nih.gov/41224659/Actively Recruiting
Led by NMD Pharma A/S · Updated on 2026-08-21
84
Participants Needed
40
Research Sites
N/A
Total Duration
Researchers are evaluating the safety and effects of three different doses of the drug NMD670 compared to a placebo in adults with Myasthenia Gravis who have antibodies against AChR or MuSK. This Phase 2 proof-of-concept study aims to find the appropriate dose by assessing how the drug affects muscle strength over 21 days of treatment. Participants will take either a high, mid, or low dose of NMD670 tablets, or placebo tablets, twice daily for 21 days. The study is randomized and double-blinded, meaning neither participants nor researchers know who receives which dose. The goal is to compare the changes in muscle strength and other symptoms between the different dose groups and placebo during this treatment period. During the study, participants will be monitored for changes in muscle strength using the Quantitative Myasthenia Gravis QMG score and other related clinical assessments. Safety will be closely watched through physical exams, lab tests, vital signs, ECGs, and eye exams from screening through follow-up. The study also tracks any adverse events during the 21-day dosing and follow-up period. Participants will be involved in visits and assessments throughout the trial, which is expected to complete by December 2026.
CONDITIONS
Safety and Efficacy of 3 Dose Levels of NMD670 in Adult Patients With Myasthenia Gravis
N
NMD Pharma A/S
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here
NMD Pharma A/S
Lead Sponsor
This table compares participation in this trial with other options available for this condition. The information is drawn from published research and the trial’s study details and is provided for educational purposes only.
| Factors | NMD670 (any dose) | Placebo | Standard‑of‑care |
|---|---|---|---|
| What it is | An investigational oral small‑molecule ClC‑1 (chloride channel) inhibitor given twice daily at three dose levels | Oral placebo given twice daily in the same schedule as investigational drug | Current standard MG care typically begins with cholinesterase inhibitors and moves on to immunosuppressive therapy as needed |
| Role in trial | Investigational treatment under evaluation in randomized arms | Placebo comparator arm | Benchmark of how MG is commonly treated outside the trial |
| Primary use | To test if NMD670 improves muscle strength and function over 21 days in antibody‑positive MG | Control to assess effects of active treatment versus no drug | Used routinely to manage MG symptoms and reduce autoimmune activity |
| How it is given/performed | Oral tablets taken twice daily for 21 days | Oral placebo tablets taken twice daily for 21 days | Pyridostigmine and immunosuppressive medicines taken as prescribed by clinicians |
| Evidence status | Early phase data show improved muscle function and target engagement in MG patients | No therapeutic effect expected; serves as control arm | Effectiveness supported by international consensus guidance using a stepwise treatment approach |
| Important risks | Safety and tolerability being evaluated; earlier data suggest acceptable profile in small studies | No pharmacologic risk but lacks therapeutic benefit | Immunosuppressive therapies carry known risks of infection and steroid side effects |
| Important limitations | Benefit and optimal dose not yet established beyond 21‑day treatment window | No therapeutic effect available and only useful for controlled comparison | Not evaluated in this trial; comparisons are indirect |
| Patient impact | May improve muscle strength and fatigue over short course, but longer benefit unknown | No direct benefit expected | Provides symptom relief and disease control over time through established therapies |
Disclaimer: This comparison is created with the help of artificial intelligence(AI) and may contain errors or missing information. It is not medical advice and does not mean one option is better or safer than another. Clinical trials are still being studied, and joining a trial is your choice. Please consult your healthcare professional before making any decisions.
You may qualify if you...
You will not qualify if you...
Duration - Up to 4 weeks
Participants are screened for eligibility to participate in the trial.
1 visit
Duration - 21 days
Participants take tablets of NMD670 or placebo twice daily for 21 days to evaluate safety and effects on muscle strength.
Regular visits during dosing
Duration - Up to 7 days after treatment
Participants are monitored for safety and any side effects through physical exams, lab tests, and eye examinations after treatment ends.
1 follow-up visit
Study Type
INTERVENTIONAL
Masking
TRIPLE
Allocation
RANDOMIZED
Model
PARALLEL
Primary Purpose
TREATMENT
Number of Arms
4
Have more questions? Get in touch with our team for quick support
Kathryn R Moss, Fereshteh B Darvishi, Yomna Badawi...
https://pubmed.ncbi.nlm.nih.gov/41224659/NMD Pharma A/S
Lead Sponsor